←Back to Expert Scholars
Translational Medicine / 转化医学CDK12 Synthetic Lethality
Christopher Heery
MD
🏢Precigen🌐USA
Chief Medical Officer
40
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Christopher Heery has led clinical development programs targeting DNA damage repair deficient cancers including CDK12 mutant prostate cancer. His work spans immunotherapy and targeted agents for tumors with genomic instability. He combines regulatory expertise with early phase trial design to advance synthetic lethal strategies.
Share:
🧪Research Fields 研究领域
clinical development
CDK12
immunotherapy
targeted therapy
prostate cancer
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Christopher Heery 的研究动态
Follow Christopher Heery's research updates
留下邮箱，当我们发布与 Christopher Heery（Precigen）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment